- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07270562
ORbital Atherektomi for Læsjonforberedelse hos Pasienter med Kronisk Livstruende Iskemi (ORACLE)
ORbital Atherektomi for lesjonsforberedelse hos pasienter med kronisk livstruende ishemi
ORACLE is a Europe-wide study that will follow 250 people with critical limb-threatening ischemia (CLTI). It aims to see how well orbital atherectomy (OA) works in real-life practice. OA is a procedure that uses a tiny spinning tool to gently remove hard calcium from inside an artery, helping to open the vessel so other treatments-like balloons or stents-can work better. The study focuses on people who have heavily calcified arteries in the femoropopliteal or infrapopliteal areas of the leg.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Claire Poulet, PhD
- Telefonnummer: +41 79 385 16 78
- E-post: oracue@cirse.org
Studer Kontakt Backup
- Navn: Dhwani S. Korde, PhD
- Telefonnummer: +4367762942469
- E-post: oracue@cirse.org
Studiesteder
-
-
-
Hull, Storbritannia, HU3 2JZ
- Rekruttering
- Hull University Teaching Hospitals NHS Trust
-
Hovedetterforsker:
- Raghu Lakshminarayan, Dr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Adult CLTI patients with femoropopliteal or infrapopliteal calcified lesions treated with OA using the Stealth 360 Peripheral OA System for vessel preparation prior to any adjunctive endovascular procedure.
Beskrivelse
Inclusion Criteria:
- Rutherford classification category ≥4;
- Treatment of femoropopliteal or infrapopliteal calcified lesions with OA using the Stealth 360 peripheral OA System;
- Calcification of target lesions must be visible on fluoroscopy or CT-angiography;
- Patients competent and willing to provide informed consent.
Exclusion Criteria:
- Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);
- Inadequate inflow (>30% stenosis) following optimization;
- Insufficient direct outflow (less than 1 run-off vessel);
- Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;
- Patients planned to receive an above ankle amputation of the target limb;
- Patients enrolled in RESCUE (ClinicalTrials.gov ID NCT07270575).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Adult CLTI patients with femoropopliteal or infrapopliteal calcified lesions
Eligible patients are those who will undergo OA prior to any adjunctive endovascular procedure |
The Stealth 360™ Peripheral Orbital Atherectomy System uses a diamond-coated, eccentrically mounted crown with bi-directional capabilities that treat a wide range of vessels, enabling single device treatment of multiple lesions and vessel sizes.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of lesions with ≤30% residual stenosis after completion of full planned procedure
Tidsramme: Immediately after procedure completion
|
Defined as residual stenosis ≤30%, immediately after completion of full planned procedure (OA + any planned adjunctive intervention(s)). |
Immediately after procedure completion
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of lesions with ≤30% residual stenosis after any unplanned endovascular intervention(s)
Tidsramme: Immediately after procedure completion
|
Defined as residual stenosis ≤30% immediately after completion of additional unplanned endovascular intervention(s) (any endovascular procedure that was not part of the primary procedure plan). |
Immediately after procedure completion
|
|
Need for unplanned bailout stenting
Tidsramme: Immediately after procedure completion
|
Defined as any stent placement that was not part of the primary procedure plan. |
Immediately after procedure completion
|
|
Number of participants free from Clinically-Driven Target Lesion Revascularization (CD-TLR)
Tidsramme: 12 and 24 months
|
Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
12 and 24 months
|
|
CD-TLR-free survival
Tidsramme: Until the end of the follow-up period of 2 years
|
Defined as time between first OA procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
Until the end of the follow-up period of 2 years
|
|
Clinical response using Rutherford classification categories
Tidsramme: 12 and 24 months
|
The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss. |
12 and 24 months
|
|
Wound status
Tidsramme: 12 and 24 months
|
Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening). |
12 and 24 months
|
|
Freedom from amputation of the target limb
Tidsramme: 12 and 24 months
|
Defined as absence of any amputation of the target limb (above ankle). |
12 and 24 months
|
|
Amputation-free survival
Tidsramme: Until the end of the follow-up period of 2 years
|
Defined as time between first OA procedure and above-ankle amputation of the target limb. |
Until the end of the follow-up period of 2 years
|
|
Overall survival
Tidsramme: Until the end of the follow-up period of 2 years
|
Defined as the time between the first OA procedure and death of any cause. |
Until the end of the follow-up period of 2 years
|
|
Patient-reported health-related quality-of-life
Tidsramme: Baseline, 6, 12 and 24 months post treatment
|
Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD. |
Baseline, 6, 12 and 24 months post treatment
|
|
Frequency and severity of procedural complications and other adverse events
Tidsramme: Within 30 days after the OA procedure
|
Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe. |
Within 30 days after the OA procedure
|
|
Clinical response using ankle-brachial index (ABI)
Tidsramme: 12 and 24 months
|
The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease. |
12 and 24 months
|
|
Clinical response using toe pressure
Tidsramme: 12 and 24 months
|
The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion. |
12 and 24 months
|
|
Clinical response using WIfi (wound, ischemia and foot infection) score
Tidsramme: 12 and 24 months
|
The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization. |
12 and 24 months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: Gerd Grözinger, Prof. Dr. med., SLK Kliniken Heilbronn GmbH
- Studiestol: Marianne Brodmann, Univ.-Prof. Dr. med., Medizinische Universität Graz
- Studiestol: Stefan Müller-Hülsbeck, Prof. Dr. med., DIAKO Krankenhaus gGmBH
- Studiestol: Raghu Lakshminarayan, Dr, Hull University Teaching Hospitals NHS Trust
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Nordanstig J, Wann-Hansson C, Karlsson J, Lundstrom M, Pettersson M, Morgan MB. Vascular Quality of Life Questionnaire-6 facilitates health-related quality of life assessment in peripheral arterial disease. J Vasc Surg. 2014 Mar;59(3):700-7. doi: 10.1016/j.jvs.2013.08.099. Epub 2013 Dec 15.
- Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse Quality Assurance Document and Standards for Classification of Complications: The Cirse Classification System. Cardiovasc Intervent Radiol. 2017 Aug;40(8):1141-1146. doi: 10.1007/s00270-017-1703-4. Epub 2017 Jun 5.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ORACLE
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .